Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer

Journal of Chemotherapy

Volumn 15, Issue 3, 2003, Pages 275-281

  Bamias, Aristotle ^a,d   Papamichael, D ^b   Syrigos, K ^c   Pavlidis, N ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b Bank of Cyprus Group Oncology Centre   (Cyprus)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

Advanced colorectal and gastric cancer; Combination chemotherapy; Irinotecan; Mitomycin C; Second line chemotherapy; Third line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ATROPINE; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; MITOMYCIN C;

ACUTE CHOLINERGIC SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHOLINERGIC STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING;

EID: 0038721792     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.3.275     Document Type: Article

References (36)

1. McKean-Cowdin R, Feigelson HS, Ross KR, et al. Declining cancer rates in the 1990s. J Clin Oncol 2000; 18: 2258-68.
2. Sumpter K, Cunningham D. Combination chemotherapy and colorectal cancer. Sem Oncol 2000; 27(5)(Suppl 10): 105-11.
3. Bamias A, Pavlidis N. Systemic chemotherapy in gastric cancer: Where do we stand today? Oncologist 1998; 3: 171-7.
4. Machover D. A comprehensive review of 5-fluorouracil and leucovorin on patients with metastatic colorectal carcinoma. Cancer 1997; 80: 1179-87.
5. De Gramont A, Louvet C, Andre T, et al. from the Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouarcil 48-h continuous infusion in advanced colorectal cancer: Evolution of a regimen. Eur J Cancer 1998; 34(5): 619-26.
6. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-7.
7. De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin 5-FU bolus with bimonthly high-dose leucovorin and 5-fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study. J Clin Oncol 1997; 15: 808-13.
8. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fiuorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-57.
9. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of Fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-11.
10. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-18.
11. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
12. Van Cutsen E, Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5 fluorouracil (5FU). Eur J Cancer 1999; 35:54-9.
13. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fiuorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-7.
14. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000, 343: 905-14.
15. Ducreux M, Ycchou M, Seitz JF, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose finding and pharmacokinetic study in patients with pre-treated metastatic colorectal cancer. J Clin Oncol 1999; 17:2901-8
16. Ogawa M. New systemic drugs in the treatment of gastrointestinal cancer. Curr Opin Oncol 1996; 8: 317-20.
17. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-23.
18. Shirao K, ShimadaY, Kondoh H, et al. Phase I-II study of ironotecan hydrocloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921-7.
19. Yaeger TE, Brady LW. Basis for current major therapies for cancer. In: Lenhard RE, Osteen RT, Gansler T, eds. Clinical Oncology, The American Cancer Society's Textbook of Cancer. Atlanta: The American Cancer Society, 2001: 175-229.
20. Ross P, Norman A, Cunningham D, et al. A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001.
21. Kano Y, Suzuki K, Akutsu M et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 1992; 50: 604-10.
22. Gil-Delgado MA, Antoine EC, Bassot V, et al. Final results of a phase I-II of CPT-11 (CPT) + Mitomycin C (MMC) combination in patients with advanced cancer of the gastrointestinal system. Proc Am Soc Clin Oncol 1998; 17, 268a (abstr 1030).
23. Yamao T, Shirao K, Matsumura Y, et al. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol 2001; 12: 1729-35.
24. Villanova-Callero MA, Kuhn J, Drengler R, et al. Pharmacologically-based phase I study of Mitomycin C (MMC) as modulator of irinotecan (CPT-11) antitumor activity. Proc Am Soc Clin Oncol 2001; 20: 101a (abstr 400).
25. Miller AB, Hoogstrater B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47: 207-14.
26. Guidelines for the Reporting of Adverse Drug Reactions. Bethesda: Division of Cancer Treatment. National Cancer Institute, 1988. Available at: http://ctep.cancer.gov. Accessed on June 1, 1999.
27. Gehan EA. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961, 13: 346-53.
28. Armitage P, Berry G. Statistical methods in medical research; Blackwell Scientific Publications; Oxford, United Kingdom, 1994.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53: 457-81.
30. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemoptherapy. J Clin Oncol 1997, 15: 251-60.
31. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997, 15: 2910-9.
32. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996, 14: 1128-35.
33. Comella P, Biglietto M, Casaretti R, et al. Irinotecan and Mitomycin C in 5-Fluorouracil-refractory colorectal cancer patients. Oncology 2001, 60: 127-33.
34. Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999, 17: 902-6.
35. Bamias A, Cunningham D, Nicolson V, et al. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin & infusional 5-fluorouracil (ECF): A Royal Marsden pilot study. Br J Cancer 1995, 71(3): 583-7.
36. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral Fluoropyrimidine anticancer drug S-1 (1M Tegafur-0,4M Gimestat-1M Otastat Potassium) in advanced gastric cancer patients. Eur J Cancer 1998, 34(11): 1715-20.